Usage of Wilms ’ Tumor 1 (WT1) Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Normal Karyotype (AML-NK) Patients

Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment evaluation and MRD monitoring. Above all, the usage of WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients, can lead to more adapted, personalized treatment protocols. Teaser The aim of this study was to test the possibility for the usage of WT1 expression level as an additional biomarker for prognosis and minimal-residual-disease (MRD) monitoring in AML-NK patients. We found that overexpression of WT1 had negative impact on treatment outcome. It was a suitable marker for MRD monitoring, and marker for refined risk stratification of AML-NK patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research